• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nephros Inc.

    6/17/24 5:18:09 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care
    Get the next $NEPH alert in real time by email
    S-8 1 forms-8.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    Under the Securities Act of 1933

     

    NEPHROS, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   13-3971809

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification Number)

     

    380 Lackawanna Place
    South Orange, New Jersey 07079

    (Address of Principal Executive Offices and Zip Code)

     

     

     

    Nephros, Inc. 2024 Equity Incentive Plan

    (Full Title of the Plan)

     

     

     

    Judy Krandel

    Chief Financial Officer

    Nephros, Inc.

    380 Lackawanna Place

    South Orange, New Jersey 07079

    (201) 343-5202

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

     

    Copies to:

    Christopher J. Melsha, Esq.

    Edward M. Peilen, Esq.

    Fredrikson & Byron, P.A.

    60 South Sixth Street, Suite 1500

    Minneapolis, MN 55402

    Telephone: (612) 492-7000

    Facsimile: (612) 492-7077

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

    Large accelerated filer ☐   Accelerated filer ☐
    Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     
     

     

    PART I

     

    The documents containing the information specified in Part I of Form S-8 are omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. Such documents will be delivered to the participants in the plan covered by this Registration Statement as required by Rule 428. These documents and the documents incorporated by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, previously filed with the Securities and Exchange Commission (the “Commission”), are hereby incorporated by reference herein:

     

      ● the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed on March 15, 2024;
         
      ● the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed on May 9, 2024;
         
      ● the Registrant’s Current Report on Form 8-K filed on May 24, 2024;
         
      ● the Registrant’s definitive Proxy Statement on Schedule 14A filed on April 12, 2024; and
         
      ● the description of the Registrant’s common stock contained in its Registration Statement on Form 8-A filed on August 13, 2019, under the Exchange Act, including any amendment or report filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all such securities then remaining unsold, shall be deemed incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof to the extent that a statement contained herein (or in any other subsequently filed document which also is incorporated by reference herein) modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed to constitute a part hereof except as so modified or superseded.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145 of the Delaware General Corporation Law (the “DGCL”) permits a corporation, under specified circumstances, to indemnify its directors, officers, employees or agents against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by them in connection with any action, suit or proceeding brought by third parties by reason of the fact that they were or are directors, officers, employees or agents of the corporation, if such directors, officers, employees or agents acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reason to believe their conduct was unlawful. In a derivative action, that is one by or in the right of the corporation, indemnification may be made only for expenses actually and reasonably incurred by directors, officers, employees or agents in connection with the defense or settlement of an action or suit, and only with respect to a matter as to which they will have acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification will be made if such person will have been adjudged liable to the corporation, unless and only to the extent that the court in which the action or suit was brought will determine upon application that the defendant directors, officers, employees or agents are fairly and reasonably entitled to indemnity for such expenses despite such adjudication of liability.

     

     
     

     

    Our Fourth Amended and Restated Certificate of Incorporation, as amended, provides for indemnification of our directors and officers of the registrant to the fullest extent permitted by the DGCL. Our Second Amended and Restated By-Laws provides that we will generally indemnify our directors, officers, employees or agents to the fullest extent permitted by law against all losses, claims, damages or similar events. We have obtained liability insurance for each director and officer for certain losses arising from claims or charges made against them while acting in their capacities as directors or officers of our company.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit No.   Description
    5.1   Opinion of Fredrikson & Byron, P.A.
    23.1   Consent of Baker Tilly US, LLP, Independent Registered Public Accounting Firm.
    23.2   Consent of Fredrikson & Bryon, P.A. (included in Exhibit 5.1)
    24.1   Power of Attorney (included on signature page hereof)
    99.1   Nephros, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on May 24, 2024).
    107   Filing Fee Table

     

    Item 9. Undertakings.

     

      (a) The undersigned Registrant hereby undertakes:

     

      (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
         
      (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement;
         
      (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

      (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
         
      (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

      (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
         
      (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by final adjudication of such issue.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South Orange, State of New Jersey, on June 17, 2024.

     

      NEPHROS, INC.
         
      By: /s/ Robert Banks
      Name:  Robert Banks
      Title: President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    The undersigned directors and officers of Nephros, Inc. hereby severally constitute and appoint Robert Banks and Judy Krandel as attorneys-in-fact for the undersigned, each of them singly, with full and several power of substitution for, and in the name, place and stead of the undersigned, to sign and file with the Securities and Exchange Commission under the Securities Act, any and all amendments (including post-effective amendments) and exhibits to this registration statement on Form S-8 (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act) and any and all applications and other documents to be filed with the Securities and Exchange Commission pertaining to the registration of the securities covered hereby, with full power and authority to do and perform any and all acts and things whatsoever requisite and necessary or desirable, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Robert Banks   President, Chief Executive Officer and Director   June 17, 2024
    Robert Banks   (Principal Executive Officer)    
             
    /s/ Judy Krandel   Chief Financial Officer   June 17, 2024
    Judy Krandel   (Principal Financial and Accounting Officer)    
             
    /s/ Arthur H. Amron   Director   June 17, 2024
    Arther H. Amron        
             
    /s/ Joseph Harris   Director   June 17, 2024
    Joseph Harris        
             
    /s/ Alisa Lask   Director   June 17, 2024
    Alisa Lask        
             
    /s/ Oliver Spandow   Director   June 17, 2024
    Oliver Spandow        

     

     

     

    Get the next $NEPH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    5/30/24 4:35:22 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    5/16/24 4:49:44 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Amron Arthur H bought $17,130 worth of shares (7,000 units at $2.45) and acquired 91,463 shares (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    3/14/24 4:28:20 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nettis Lisa Marie was granted 1,622 shares (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    11/13/25 5:00:38 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Director Spandow Oliver J. was granted 8,036 shares, increasing direct ownership by 7% to 122,881 units (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    11/13/25 4:59:35 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Director Amron Arthur H was granted 5,391 shares, increasing direct ownership by 4% to 131,272 units (SEC Form 4)

    4 - NEPHROS INC (0001196298) (Issuer)

    11/13/25 4:58:35 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    SEC Filings

    View All

    Nephros Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

    8-K - NEPHROS INC (0001196298) (Filer)

    11/26/25 4:15:32 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Nephros Inc.

    10-Q - NEPHROS INC (0001196298) (Filer)

    11/6/25 4:01:11 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEPHROS INC (0001196298) (Filer)

    8/11/25 4:15:32 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley FBR initiated coverage on Nephros with a new price target

    B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50

    1/26/21 6:12:57 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nephros Launches the Nephros Water Institute to Lead National Water Safety Education

    SOUTH ORANGE, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leader in point-of-use water filtration, today announced the launch of the Nephros Water Institute, a dedicated education initiative established to formalize the company's leadership in industry education. In 2025, Nephros accelerated its national education efforts under the direction of Brianne McGuire, Director of Business Development. Through high-engagement public webinars, national speaking engagements, and tailored trainings with healthcare systems and consulting partners, Nephros directly reached nearly 1,000 professionals. The regulatory and risk-based educational programming addressed critical bl

    12/11/25 9:00:00 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Announces Strong Third Quarter Financial Results; Achieving Highest Level of Programmatic Sales in Company History

    Third-Quarter Net Revenue of $4.8 million; Robust Growth Drives 35% Increase in Net Revenue and Fourth Consecutive Quarter of Profitability SOUTH ORANGE, NJ., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2025. Financial Highlights Net revenue increased 35% to $4.8 million compared to $3.5 million in the third quarter of 2024Net income increased 84% to $337,000, compared to $183,000 in the third quarter of 2024Adjusted EBITDA increased 42% to $418,000, compared to $295,000 in the third quarte

    11/6/25 4:10:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    ¬Nephros Schedules Third Quarter 2025 Financial Results Conference Call

    SOUTH ORANGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 6, 2025 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

    10/30/25 4:00:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nephros Inc.

    SC 13G - NEPHROS INC (0001196298) (Subject)

    2/3/23 3:15:24 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Nephros Inc.

    SC 13G - NEPHROS INC (0001196298) (Subject)

    2/3/23 3:13:44 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Nephros Inc.

    SC 13G - NEPHROS INC (0001196298) (Subject)

    2/3/23 3:11:33 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    $NEPH
    Leadership Updates

    Live Leadership Updates

    View All

    Nephros Hires Judy Krandel as Chief Financial Officer

    SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv

    11/1/23 7:30:00 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Appoints Joe Harris to Its Board of Directors

    SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment

    9/8/22 4:00:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    RION Appoints Alisa Lask as Chief Commercial Officer

    - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

    1/14/22 9:00:00 AM ET
    $CLGN
    $NEPH
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $NEPH
    Financials

    Live finance-specific insights

    View All

    ¬Nephros Schedules Third Quarter 2025 Financial Results Conference Call

    SOUTH ORANGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 6, 2025 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

    10/30/25 4:00:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Announces Strong Second Quarter Financial Results

    SOUTH ORANGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2025. Financial Highlights Net revenue was $4.4 million, compared to $3.3 million in the second quarter of 2024, up 36%Net income was $237,000, compared to a net loss of ($289,000) in the second quarter of 2024Adjusted EBITDA was $355,000, compared to ($133,000) in the second quarter of 2024 For the six months ended June 30, 2025: Net revenue was $9.3 million, compared to $6.8 million in the same period of 2024, up 37%Net income w

    8/7/25 4:00:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    Nephros Schedules Second Quarter 2025 Financial Results Conference Call

    SOUTH ORANGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 07, 2025 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of

    7/31/25 4:00:00 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care